Key result
Efonidipine preserved renal function and significantly reduced arterial stiffness and oxidative stress compared to amlodipine over 12 months in type 2 diabetic patients with hypertension and nephropathy.
Why the study?
Does efonidipine improve renal function and arterial stiffness compared to amlodipine in type 2 diabetic patients with hypertension and nephropathy?
Population
40 type 2 diabetic patients with hypertension and nephropathy receiving angiotensin receptor II blockers…
Comparison
Efonidipine hydrochloride ethanolate 40 mg/day… vs Amlodipine besilate 5 mg/day oral for 12 months…
Design
RCT, Randomization was performed with sequentially numbered, sealed envelopes…
Follow-up
12 months
Authors
Loading...
Efonidipine may be preferred over amlodipine in diabetic hypertensive nephropathy; extends randomized CCB comparisons with renal and stiffness endpoints.
RCT (n=40)
Open-label
Randomized
No
Does efonidipine improve renal function and arterial stiffness compared to amlodipine in type 2 diabetic patients with hypertension and nephropathy?
In type 2 diabetic patients with hypertension and nephropathy, efonidipine (a T- and L-type CCB) preserved renal function and reduced arterial stiffness compared to amlodipine, potentially due to its oxidative stress-reducing and aldosterone-lowering effects.
Sasaki et al. (2009) conducted an RCT in Type 2 diabetes with hypertension and nephropathy (n=40). Efonidipine vs. Amlodipine 5 mg/day was evaluated on Renal function (serum creatinine, urinary albumin, eGFR) and arterial stiffness (CAVI). Efonidipine preserved renal function and significantly reduced arterial stiffness and oxidative stress compared to amlodipine over 12 months in type 2 diabetic patients with hypertension and nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: